Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
Axonics Modulation Technologies Inc Market Cap
Based on ratings from 6 stock analysts, the Axonics Modulation Technologies Inc stock price is expected to increase by 4.21% in 12 months. This is calculated by using the average 12-month stock price forecast for Axonics Modulation Technologies Inc. The lowest target is $71.00 and the highest is $71.00. Please note analyst price targets are not guaranteed and could be missed completely.
AXNX is a stock in Health Care which has been forecasted to be worth $71.00 as an average. On the higher end, the forecast price is $71.00 USD by matthew mishan from KeyBanc and on the lower end AXNX is forecasted to be $71.00 by matthew mishan from KeyBanc.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| michael matson Needham | Hold | None | downgraded | Jan 17, 2024 |
| kallum titchmarsh Morgan Stanley | Hold | $71.0 | downgraded | Jan 16, 2024 |
| kristen stewart C.L. King | Hold | None | downgraded | Jan 12, 2024 |
| adam maeder Piper Sandler | Hold | $71.0 | downgraded | Jan 12, 2024 |
| richard newitter Truist Financial | Hold | $71.0 | downgraded | Jan 12, 2024 |
| shagun singh chadha RBC Capital | Hold | $71.0 | maintained | Jan 11, 2024 |
| mike kratky Leerink Partners | Hold | $71.0 | downgraded | Jan 11, 2024 |
| larry biegelsen Wells Fargo | Hold | $71.0 | downgraded | Jan 10, 2024 |
| michael polark Wolfe Research | Hold | None | downgraded | Jan 8, 2024 |
| travis steed Bank of America Securities | Buy | $75.0 | reiterated | Oct 31, 2023 |
| anthony petrone Mizuho Securities | Buy | $75.0 | reiterated | Oct 31, 2023 |
| david rescott Robert W. Baird | Buy | $70.0 | rated | Oct 30, 2023 |
| matthew mishan KeyBanc | Buy | $71.0 | reiterated | Jul 28, 2023 |
| michael sarcone Jefferies | Hold | $55.0 | reiterated | May 30, 2023 |
| cecilia furlong Morgan Stanley | Buy | $76.0 | rated | Jan 11, 2023 |
| matthew taylor UBS | Hold | $75.0 | initiatedcoverage | Oct 12, 2022 |
| christopher pasquale Nephron | Buy | $75.0 | initiatedcoverage | Jul 12, 2022 |
| danielle antalffy SVB Securities | Buy | $80.0 | maintained | May 6, 2022 |
| bob hopkins Bank of America Securities | Buy | $65.0 | reiterated | Mar 1, 2021 |
| bruce nudell Truist Financial | Buy | $33.0 | maintained | May 10, 2019 |
Axonics, Inc., a medical technology company, engages in the development and commercialization of novel products for the treatment of bladder and bowel dysfunction. Its sacral neuromodulation (SNM) systems are used to treat patients with overactive bladder (OAB), including urinary urge incontinence and urinary urgency frequency, as well as fecal incontinence (FI) and non-obstructive urinary retention (UR); and rechargeable (R20) and recharge-free (F15) implantable SNM systems that delivers mild electrical pulses to the targeted sacral nerve to restore normal communication to and from the brain to reduce the symptoms of bladder and bowel dysfunction. reduce the symptoms of OAB, UR, and FI. The company also offers Bulkamid, a urethral bulking agent to treat female stress urinary incontinence. It sells its products through a direct sales force and distributors in the United States, the United Kingdom, Germany, the Netherlands, Nordic countries, and internationally. The company was formerly known as Axonics Modulation Technologies, Inc. and changed its name to Axonics, Inc. in March 2021. Axonics, Inc. was incorporated in 2012 and is based in Irvine, California.
When did it IPO
2018
Staff Count
610
Country
United States
Sector/Industry
Healthcare/Medical Devices
CEO
Mr. Raymond W. Cohen
Market Cap
$3.45B
In 2023, AXNX generated $0 in revenue, which was a increase of 0.00% from the previous year. This can be seen as a signal that AXNX's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2019
Revenue From 2020
Revenue From 2021
Revenue From 2022
ALRM-USD
$69.98
BL-USD
$56.72
ITRI-USD
$75.4
RELY-USD
$18.38
MQ-USD
$6.52
$12.39
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
